drugset / Trial / NCT00730392

Etanercept in New Onset Type 1 Diabetes

NCT00730392

RandomizedParallel-groupTriple-blindTreatment

Summary

The investigators hypothesized that the administration of Etanercept to children newly diagnosed with T1DM may be able to interdict the progression of T1DM. The aim of this study is to evaluate the feasibility and safety of Etanercept administration to pediatric patients recently diagnosed with type 1 DM.

Timeline

Start
2002-10
Primary completion
2007-10
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 0.4 mg/kg Subcutaneous